Last reviewed · How we verify
Sacubitril-valsartan
At a glance
| Generic name | Sacubitril-valsartan |
|---|---|
| Also known as | Entresto, ARNI therapy, LCZ696, Valsartan |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
- Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (PHASE1)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (PHASE1, PHASE2)
- A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sacubitril-valsartan CI brief — competitive landscape report
- Sacubitril-valsartan updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI